Buerger disease often involves repeated acute episodes of ischemia over several years. The disease intensifies at 30 to 40 years of age and then regresses. It is rarely present in patients >60 years of age.[62]Szuba A, Cooke JP. Thromboangiitis obliterans: an update on Buerger's disease. West J Med. 1998 Apr;168(4):255-60.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1304949/pdf/westjmed00331-0029.pdf
http://www.ncbi.nlm.nih.gov/pubmed/9584663?tool=bestpractice.com
Smoking cessation
Patients who continue to smoke have a 19% major amputation rate; this is 2.73 times greater than for people who have ceased smoking, according to one study.[32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80.
http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com
[34]Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol. 2000 Aug 31;75(suppl 1):S175-81.
http://www.ncbi.nlm.nih.gov/pubmed/10980360?tool=bestpractice.com
Smoking increases flare-ups and reduces ulcer healing. A return to smoking following cessation may lead to a flare-up of the disease. Smoking only 1 or 2 cigarettes a day, using smokeless tobacco (chewing tobacco), or using nicotine replacement therapy may all keep the disease active.[19]Lie JT. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum. 1988 Jun;31(6):812-3.
http://www.ncbi.nlm.nih.gov/pubmed/3382454?tool=bestpractice.com
[20]Joyce JW. Buerger's disease (thromboangiitis obliterans). Rheum Dis Clin North Am. 1990 May;16(2):463-70.
http://www.ncbi.nlm.nih.gov/pubmed/2189162?tool=bestpractice.com
Smoking is best stopped through smoking cessation classes, although varenicline has been shown to be beneficial. Varenicline is a selective nicotinic receptor partial agonist that is used as an aid for smoking cessation.
Amputations
In one study, 34% of patients had an amputation within 15 years of diagnosis.[2]Le Joncour A, Soudet S, Dupont A, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger's disease): a multicenter study of 224 patients. J Am Heart Assoc. 2018 Dec 4;7(23):e010677.
https://www.doi.org/10.1161/JAHA.118.010677
http://www.ncbi.nlm.nih.gov/pubmed/30571594?tool=bestpractice.com
The amputation-free survival rates at 5 and 10 years were 85% and 74%, respectively. Limb infection was associated with an increased amputation rate.[2]Le Joncour A, Soudet S, Dupont A, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger's disease): a multicenter study of 224 patients. J Am Heart Assoc. 2018 Dec 4;7(23):e010677.
https://www.doi.org/10.1161/JAHA.118.010677
http://www.ncbi.nlm.nih.gov/pubmed/30571594?tool=bestpractice.com
Repeated amputations are often needed and are an indication of the disease severity.
Life expectancy
Life expectancy is not altered in patients with Buerger disease: 90% to 95% survive 10 years; 85% survive 25 years.[1]Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). Ann Vasc Surg. 1991 Nov;5(6):570-2.
http://www.ncbi.nlm.nih.gov/pubmed/1772769?tool=bestpractice.com
[32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80.
http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com
[63]Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vascular diseases in northeastern of Turkey: thromboangiitis obliterans or Buerger's disease (experience with 344 cases). Int J Cardiol. 2006 Jul 28;111(1):147-53.
http://www.ncbi.nlm.nih.gov/pubmed/16580754?tool=bestpractice.com
This is probably because Buerger disease is not associated with cardiovascular risk factors, aside from smoking.